Brentuximab Vedotin News and Research

RSS
Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

Blood cancer drug trial results questioned by FDA

Blood cancer drug trial results questioned by FDA

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

EMA accepts Millennium's MAA for ADCETRIS to treat lymphoma

EMA accepts Millennium's MAA for ADCETRIS to treat lymphoma

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.